HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Name: HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
Published: 2025
License: Public Domain

Princess Maxima Center for Pediatric Oncology · 2025

ClinicalTrials.gov · Datasets · License: Public Domain · 2025

Open Source ↗

adolescents chemotherapy

acute lymphoblastic leukemia, lymphoblastic lymphoma (precursor b-lymphoblastic lymphoma/leukaemia) recurrent, lymphoblastic lymphoma (precursor t-lymphoblastic lymphoma/leukaemia) recurrent, lymphoblastic lymphoma (precursor b-lymphoblastic lymphoma/leukaemia) refractory, lymphoblastic lymphoma (precursor t-lymphoblastic lymphoma/leukaemia) refractory, relape, biomarker driven clinical trial, dasatinib, refractory, chemotherapy, children, adolescents

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

Related documents